Loading data for CING — first visit, this takes a few seconds.
Cingulate Inc. (CING)
NasdaqCM: CING
· Real-Time Price · USD
5.55
+0.22 (4.13%)
At close: Aug 20, 2026, 3:59 PM
5.57
+0.36%
After-hours: 6:18 PM
The price, the headline numbers and the latest news, in one place.
Cingulate Inc. (CING) Stock Price, Analysis & Data
4.13% (1D)
| Bid | 3.95 |
| Market Cap | 80.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.81M |
| -0.91 | |
| -3.56 | |
| n/a | |
| -5.84 | |
| P/B (ttm) | 3.29 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 6.8 |
| Volume | 228,579 |
| Avg. Volume (20D) | 425,232 |
| Open | 5.35 |
| Previous Close | 5.33 |
| Day's Range | 5.18 - 5.55 |
| 52-Week Range | 3.16 - 11.89 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a f...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2021
Employees 14
Stock Exchange NasdaqCM
Ticker Symbol CING
Website https://www.cingulate.com
Financial Performance
In 2025, Cingulate's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -22.45M, an increase of 35.57%.
Financial StatementsEarnings Surprise
Cingulate has released their quarterly earnings on Aug 13, 2026:
